Earnings ·
CorMedix Inc. reported second quarter 2026 financial results with consolidated revenue of $101.9 million and net…
CRMDCorMedix Inc.
CorMedix Inc. reported second quarter 2026 financial results with consolidated revenue of $101.9 million and net income of $26.0 million, or $0.33 basic and $0.29 diluted EPS. Revenue comprised $66.1 million from DefenCath sales and $35.8 million from the acquired Melinta portfolio. The company raised its full-year 2026 adjusted EBITDA guidance to a range of $125 to $140 million while maintaining revenue guidance of $325 to $345 million. CorMedix also announced an anticipated FDA submission for a supplemental New Drug Application for REZZAYO in the third quarter and signed a new multi-year supply agreement with a large dialysis operator. The company operates in the biopharmaceutical industry, developing and commercializing therapeutic products for institutional care settings.